Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089347318> ?p ?o ?g. }
- W2089347318 endingPage "354" @default.
- W2089347318 startingPage "349" @default.
- W2089347318 abstract "Smokers experience aberrant gene promoter methylation in their bronchial cells, which may predispose to the development of neoplasia. Hydralazine is a DNA demethylating agent, and valproic acid is a histone deacetylase inhibitor, and both have modest but synergistic anticancer activity in vitro. We conducted a phase I trial combining valproic acid and hydralazine to determine the maximally tolerated dose (MTD) of hydralazine in combination with a therapeutic dose of valproic acid in patients with advanced, unresectable, and previously treated solid cancers. Twenty females and nine males were enrolled, with a median age of 57 years and a median ECOG performance status of 0. Grade 1 lymphopenia and fatigue were the most common adverse effects. Three subjects withdrew for treatment-related toxicities occurring after the DLT observation period, including testicular edema, rash, and an increase in serum lipase accompanied by hyponatremia in one subject each. A true MTD of hydralazine in combination with therapeutic doses of valproic acid was not reached in this trial, and the planned upper limit of hydralazine investigated in this combination was 400 mg/day without grade 3 or 4 toxicities. A median number of two treatment cycles were delivered. One partial response by Response Evaluation Criteria In Solid Tumors criteria was observed, and five subjects experienced stable disease for 3 to 6 months. The combination of hydralazine and valproic acid is simple, nontoxic, and might be appropriate for chemoprevention or combination with other cancer treatments. This trial supports further investigation of epigenetic modification as a new therapeutic strategy." @default.
- W2089347318 created "2016-06-24" @default.
- W2089347318 creator A5005238877 @default.
- W2089347318 creator A5013680322 @default.
- W2089347318 creator A5017893760 @default.
- W2089347318 creator A5030323121 @default.
- W2089347318 creator A5061746536 @default.
- W2089347318 creator A5073246708 @default.
- W2089347318 creator A5077168338 @default.
- W2089347318 creator A5080346583 @default.
- W2089347318 creator A5082131768 @default.
- W2089347318 date "2014-06-01" @default.
- W2089347318 modified "2023-09-30" @default.
- W2089347318 title "A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers" @default.
- W2089347318 cites W1516432813 @default.
- W2089347318 cites W1626483287 @default.
- W2089347318 cites W1641419369 @default.
- W2089347318 cites W1966959753 @default.
- W2089347318 cites W1971399354 @default.
- W2089347318 cites W1974369164 @default.
- W2089347318 cites W1978375723 @default.
- W2089347318 cites W1978664410 @default.
- W2089347318 cites W1984807040 @default.
- W2089347318 cites W1986965788 @default.
- W2089347318 cites W1997148771 @default.
- W2089347318 cites W1997392910 @default.
- W2089347318 cites W1999330423 @default.
- W2089347318 cites W2000431894 @default.
- W2089347318 cites W2006562902 @default.
- W2089347318 cites W2008836678 @default.
- W2089347318 cites W2015127527 @default.
- W2089347318 cites W2015886726 @default.
- W2089347318 cites W2018051857 @default.
- W2089347318 cites W2033421610 @default.
- W2089347318 cites W2038536598 @default.
- W2089347318 cites W2044433401 @default.
- W2089347318 cites W2046770376 @default.
- W2089347318 cites W2051178769 @default.
- W2089347318 cites W2106482095 @default.
- W2089347318 cites W2107972234 @default.
- W2089347318 cites W2119391432 @default.
- W2089347318 cites W2122315592 @default.
- W2089347318 cites W2124418078 @default.
- W2089347318 cites W2126425007 @default.
- W2089347318 cites W2134538813 @default.
- W2089347318 cites W2140587516 @default.
- W2089347318 cites W2141476381 @default.
- W2089347318 cites W2143742355 @default.
- W2089347318 cites W2147399332 @default.
- W2089347318 cites W2148104091 @default.
- W2089347318 cites W2148232503 @default.
- W2089347318 cites W2160829078 @default.
- W2089347318 cites W2161963925 @default.
- W2089347318 cites W2167118090 @default.
- W2089347318 cites W2318410985 @default.
- W2089347318 doi "https://doi.org/10.1016/j.tranon.2014.03.001" @default.
- W2089347318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4792814" @default.
- W2089347318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24746712" @default.
- W2089347318 hasPublicationYear "2014" @default.
- W2089347318 type Work @default.
- W2089347318 sameAs 2089347318 @default.
- W2089347318 citedByCount "25" @default.
- W2089347318 countsByYear W20893473182014 @default.
- W2089347318 countsByYear W20893473182015 @default.
- W2089347318 countsByYear W20893473182016 @default.
- W2089347318 countsByYear W20893473182017 @default.
- W2089347318 countsByYear W20893473182018 @default.
- W2089347318 countsByYear W20893473182019 @default.
- W2089347318 countsByYear W20893473182020 @default.
- W2089347318 countsByYear W20893473182021 @default.
- W2089347318 countsByYear W20893473182022 @default.
- W2089347318 crossrefType "journal-article" @default.
- W2089347318 hasAuthorship W2089347318A5005238877 @default.
- W2089347318 hasAuthorship W2089347318A5013680322 @default.
- W2089347318 hasAuthorship W2089347318A5017893760 @default.
- W2089347318 hasAuthorship W2089347318A5030323121 @default.
- W2089347318 hasAuthorship W2089347318A5061746536 @default.
- W2089347318 hasAuthorship W2089347318A5073246708 @default.
- W2089347318 hasAuthorship W2089347318A5077168338 @default.
- W2089347318 hasAuthorship W2089347318A5080346583 @default.
- W2089347318 hasAuthorship W2089347318A5082131768 @default.
- W2089347318 hasBestOaLocation W20893473181 @default.
- W2089347318 hasConcept C104317684 @default.
- W2089347318 hasConcept C118552586 @default.
- W2089347318 hasConcept C126322002 @default.
- W2089347318 hasConcept C197934379 @default.
- W2089347318 hasConcept C2776202225 @default.
- W2089347318 hasConcept C2776999253 @default.
- W2089347318 hasConcept C2777172819 @default.
- W2089347318 hasConcept C2778186239 @default.
- W2089347318 hasConcept C2778305200 @default.
- W2089347318 hasConcept C2780521442 @default.
- W2089347318 hasConcept C55493867 @default.
- W2089347318 hasConcept C64927066 @default.
- W2089347318 hasConcept C71924100 @default.
- W2089347318 hasConcept C84393581 @default.
- W2089347318 hasConcept C86803240 @default.
- W2089347318 hasConcept C90924648 @default.